Month: May 2023

SAMPO PLC                 STOCK EXCHANGE RELEASE         25/05/2023 at 08:30 am Sampo plc’s share buybacks 24/05/2023 On 24/05/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,600 43.03 AQEU  27,539 43.02 CEUX  12,722 43.04 TQEX  71,139 43.02 XHELTOTAL 120,000 43.02  *rounded to two decimals                 On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is...

SECURITIES NOTE This securities note (the “Securities Note”) is made available in connection with the offer of bonds convertible into new shares, without subscription rights and with a priority subscription period (délai de priorité), on an irreducible and reducible basis, for a gross amount of 30 million euros by issuing 200,000,000 convertible bonds at a price of 0.15 euro each to be subscribed in cash and / or by debt set-off.AttachmentArcade – Securities Note – VF (2)

Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2Sandoz continues to build its biosimilars portfolio to increase patient access to high-quality, affordable biologics and generate savings for health systemsBasel, May 25, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Medicines Agency (EMA) has accepted the marketing authorization applications (MAA) for proposed biosimilar denosumab for regulatory review. The...

Styret i RomReal Limited (RomReal) har besluttet og forlenge det frivillige tilbudet til alle RomReal aksjonærer som eier mellom 1 og til og med 1.000 aksjer med to uker til 8. juni 2023 kl 1600 norsk tid. Hensikten med tilbudet er og gi denne gruppen eiere et frivillig tilbud om å selge vederlagsfritt i et selskap med kun sporadisk og volatil omsetning. I 2022 var RomReal-aksjen kun omsatt i 141 av årets 233 børsdager. Tilbudsprisen er uforandret på NOK 2,43 pr aksje. For ytterligere detaljer, vennligst se børsmelding/ romreal.com av 11.05.23 med vedlegg inkludert akseptskjema til DNB Markets.  Styret I RomReal Limited, 24.05.2023.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

RomReal hereby announces the results of the first quarter 2023 via the Report and an Investor presentation attached to this message. For further information, pls contact investors@romreal.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsRomReal Q1 2023 ReportRomReal Q1 2023 Presentation

CALGARY, Alberta, May 24, 2023 (GLOBE NEWSWIRE) — NXT Energy Solutions Inc. (“NXT” or the “Company”) (TSX: SFD; OTCQB: NSFDF) is pleased to announce a ten-year strategic alliance and associated financing with Synergy E&P Technologies Limited (“Synergy”) which grants Synergy an exclusive license to use, distribute, sub-license, market and sell NXT’s SFD® solutions in Africa. PE Energy Limited, an affiliate of Synergy, has performed several commercial projects with NXT in Africa in the past. Synergy, with this new arrangement, will be advancing the SFD® technology to address energy security in and transition in the African continent for both oil and gas and geothermal sources. Synergy and NXT will work closely together to train local technical teams and regulatory authorities on the patented SFD® technology...

GN Store Nord A/S hereby announces that on May 25, 2023, pursuant to Section 31 of the Danish Capital Markets Act, it has decreased its aggregate holding of treasury shares to below 5% of the share capital and voting rights in GN Store Nord A/S. For further information, please contact: For further information, please contact: Investor RelationsAnne Sofie Staunsbæk Veyhe +45 45 75 85 06Rune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN brings people closer through our leading intelligent hearing, audio, video, and gaming solutions. Inspired by people and driven by innovation, we deliver technology that enhance the senses of hearing and sight. We help people with hearing loss overcome real-life challenges, improve communication and collaboration for businesses, and provide great experiences for...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING MEMORANDUM OR A PROSPECTUS AS DEFINED BY REGULATION (EU) NO. 2017/1129 OF 14 JUNE 2017. GN Store Nord A/S announces successful completion of directed issue and private placing of new shares and existing treasury shares, raising gross proceeds of approximately DKK 2.75 bn GN Store Nord A/S (“GN“) hereby announces the completion of an accelerated bookbuild process of a total of 17,319,337 shares (nominally DKK 69,277,348) of each DKK 4.00 comprising 13,719,337 new shares (the “New Shares”) and 3,600,000...